Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes

Clinical Gastroenterology and Hepatology(2021)10.1016/j.cgh.2021.07.010Source: DataRank Database

Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes is a research paper published in Clinical Gastroenterology and Hepatology (2021). On theSindex it has a DataRank of 0. It has been cited 96 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access96 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 7.14)OA: greenTopics (53)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Elisabetta Patorno ORCID,Sebastian Schneeweiß ORCID,Tracey G. Simon ORCID

Live enrichment

PubMed:34256144 OpenAlex:https://openalex.org/W3178974444

National Institutes of Health

Grant: K23 DK122104

National Institute on Aging

Grant: K08AG055670

FWCI

7.14

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8743301

publisherhttps://api.elsevier.com/content/article/PII:S1542356521007242?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1542356521007242?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cgh.2021.07.010

Fields of Study

Diabetes Treatment and ManagementLiver Disease and TransplantationHeart Failure Treatment and ManagementAscitesDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageGlucagon-Like Peptide-1 ReceptorHepatic EncephalopathyHepatorenal SyndromeHumansLiver CirrhosisMalePeritonitisRetrospective StudiesSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor Agonists

MeSH Terms

Glucagon-Like Peptide-1 ReceptorSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsAscitesDiabetes Mellitus, Type 2Esophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHepatic EncephalopathyHepatorenal SyndromeHumansLiver CirrhosisMalePeritonitisRetrospective StudiesDipeptidyl-Peptidase IV Inhibitors

Keywords

MedicineCirrhosisDecompensationDiabetes mellitusInternal medicineGlucagon-like peptide-1GlucagonEndocrinologyGlucagon-like peptide 1 receptorReceptorGastroenterologyAgonistType 2 diabetesInsulinAntidiabetic TherapyComparative EffectivenessDecompensated CirrhosisPharmacoepidemiology

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes

10.6084/m9.figshare.24940527.v1figshare

Additional file 1 of Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes

10.6084/m9.figshare.24940527figshare

Related Papers (2)

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

N/A

3.0DataRank · unranked

Nature Medicine(2023)

co-cited

10.1038/s41591-022-02200-8

Reversing pathological cell states: the road less travelled can extend the therapeutic horizon

Trends in Cell Biology(2023)

co-cited

10.1016/j.tcb.2023.04.004